Результаты поиска

Cancer in the Spine: Comprehensive Care

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Basic principles and recent concepts in the diagnosis, staging, and treatment of spinal tumours are highlighted for physicians, including internists, oncologists, neurosurgeons, and orthopaedic surgeons. …

PB2676: ARE NOVEL THERAPEUTIC OPPORTUNITIES LEADING US TO OVERTREAT PATIENTS?: A REVIEW OF END-OF-LIFE SITUATION IN HAEMATOLOGICAL PATIENTS

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Haematologists have a lower tendency to refer to palliative care compared to other specialists such as oncologists. There is a need to broaden the knowledge of palliative care to ensure the best possible quality of the last days of life. …

New insights into malignant B-cell disorders.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Conclusions: These results suggest that hematologists/oncologists may be able to use ocular symptoms and the OSDI tool as potential surrogate markers for eye exam results to help determine whether dosing changes are needed. Validation with other belamaf dose regimens is ongoing. …

Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase.

BackgroundCancer is one of the leading causes of death globally. Owing to high toxicity, patients using chemotherapy drugs have a higher risk for developing adverse drug reactions (ADRs). Pharmacovigilance studies are essential in oncology to evaluate ADRs caused by anticancer drugs and improve patient safety. This study aimed to analyze serious ADRs associated with the use of doxorubicin and epirubicin reported to VigiBase.MethodAll anonymized data on suspected ADRs for doxorubicin and epirubicin as 'serious' and 'suspected' or 'interacting' drugs between 1968 and 30 August 2021, were extract

Совпадение в полном тексте источника
… Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol 2021; 22: 1367–1377. 16. World Health Organization. World Health Organization model list of essential medicines 22nd list Geneva: World Health Organization. (No. … Oncologist 2005; 10: 780–791. 50. Balkhi B, Alqahtani S, Altayyar W, et al. Drug utilization and expenditure of anticancer drugs for breast cancer. Saudi Pharm J 2020; 28: 669–674. 51. Aagaard L, Strandell J, Melskens L, et al. Global patterns of adverse drug reactions over a decade. …

A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.

AbstractPeer support has been associated with improved patient-reported outcomes (PROs), including reduced psychological distress, among patients undergoing hematopoietic stem cell transplantation (HSCT), but structured interventions are limited. This study assessed the feasibility, acceptability, and preliminary effects of a scalable peer support intervention to reduce psychological distress and enhance quality of life (QOL) post-HSCT. We conducted a pilot randomized clinical trial evaluating the Supporting Transplant Experiences with Peer Program (STEPP), a 5-session, telephone-based interve

Совпадение в полном тексте источника
… Exclusion criteria included: nonmalignant hematologic conditions, second or outpatient HSCT, or acute psychiatric or cognitive disorders that could interfere with the ability to provide informed consent. 31 , 32 Recruitment and enrollment With oncologist approval, eligible patients were approached … support for patients with cancer, include reflective exercises and components of established psychotherapeutic approaches such as cognitive behavioral therapy, mindfulness, and positive psychology. 16 , 28 , 35 STEPP was developed by a transdisciplinary team of HSCT recipients, mental health clinicians, oncologists …

Глобальная эпидемиология и бремя множественной миеломы 1990 в адрес 2021 с прогнозами 2045 на основе глобального исследования бремени болезней 2021.

Множественная миелома (ММ) — сложная гематологическая гелингология, характеризующаяся аномальным распространением злокачественных плазменных клеток в костном мозге. Цель этого исследования состоит в том, чтобы дать всеобъемлющую оценку глобальной эпидемиологии, бремени болезней и связанных с ними факторов риска, связанных с ММ. 1990 в адрес 2021, с прогнозами 2045. МЕТОДЫ: Был проведен описательный эпидемиологический анализ с использованием данных Глобального бремени болезней (ГБЗ) 2021 исследование, включающее в себя 204 странами и территориями. Были проанализированы ключевые показатели, таки

Catheter-related thrombosis in cancer patients with tunnelled non-cuffed centrally inserted central catheters: a retrospective cohort study.

BACKGROUND: Peripherally inserted central catheters (PICCs) are widely used in oncology but are associated with higher rates of catheter-related thrombosis compared to other central venous access devices. Tunnelled non-cuffed centrally inserted central catheters (tnc-CICC) may offer a safer alternative in patient at high risk of thrombosis. METHODS: This retrospective cohort study evaluated 193 tnc-CICCs placed in 182 cancer patients at a tertiary oncology unit between January 2021 and December 2022. Primary outcomes is catheter-related thrombosis; secondary outcomes are procedural duration a

Совпадение в полном тексте источника
… Still, many oncologists prefer PICCs as central venous access device because of the ease of insertion as well as removal and the low costs [ 3 , 6 ]. … The University Hospitals Leuven is a large tertiary academic teaching facility, running a dedicated multidisciplinary and interprofessional vascular access team, consisting of surgical oncologists, vascular surgeons, interventional radiologists and specialist nurses. …

Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers.

BackgroundAging in humans is a heterogeneous process influenced by both biological and chronological factors. Biological age reflects an individual's physiological reserve and functional status. Increasing evidence suggests that cancer and its therapies accelerate biological aging. Many biomarkers have been evaluated to assess the biological age of patients with cancer. These biomarkers are emerging as potential tools to predict cancer-related toxicity and an individual's functional capacity as well as to individualize treatment.MethodsThis review summarizes the current literature on aging bio

Совпадение в полном тексте источника
… Oncologists widely use risk calculators to make treatment decisions; however, these are not precise tools to predict individual tolerance and toxicity development to various cancer therapies [ 23 , 24 ]. … B., “Chemotherapy Toxicity Risk Score for Treatment Decisions in Older Adults With Advanced Solid Tumors,” Oncologist 23, no. 5 (2018): 573–579. 19. Magnuson A., Sedrak M. S., Gross C. …

The Role of Frailty in Cardio-oncology and its Challenges.

Frailty has received increasing scientific attention as a potential explanation for adverse health outcomes among older adults. In cardio-oncology, frailty is particularly relevant due to the dual burden of cardiovascular disease and cancer, both of which accelerate the general decline in health associated with ageing. Therefore, understanding and addressing frailty in cardio-oncology has paramount importance for optimising patient outcomes, personalising treatment plans, and improving quality of life. In this review, we aim to discuss: the pathophysiology of frailty in the context of cardio-o

Совпадение в полном тексте источника
… Cardiovascular disease (CVD) and cancer are among the leading causes of mortality, particularly in older populations. 1 Cardio-oncology is a dynamic and interdisciplinary field that brings together a diverse team of specialists, including oncologists, cardiologists, and other dedicated healthcare providers … Oncologist. 2022;27:e796–803. doi: 10.1093/oncolo/oyac133. 60. Patrizio E, Calvani R, Marzetti E, Cesari M. Physical functional assessment in older adults. J Frailty Aging. 2021;10:141–9. doi: 10.14283/jfa.2020.61. 61. Warnock C, Ulman J, Skilbeck J, Tod A. …

Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN).

Myeloproliferative neoplasms (MPN) are associated with a variety of symptoms that severely impact patients' quality of life and ability to perform daily activities. Recent studies showed differences in the perception of physician- versus patient-reported symptom burden. However, studies directly comparing patient- and physician-reported ratings are lacking. Here, a retrospective analysis on symptom burden of 3979 MPN patients of the Bioregistry of the German Study Group for MPN was conducted to intra-individually compare physician and patient reports collected at the same time. Cohen's kappa w

Совпадение в полном тексте источника
… Materials and methods The German Study Group MPN Bioregistry (GSG-MPN Bioregistry) is an observational study of BCR::ABL1-negative MPN patients with over 70 participating centers, including university hospitals, community hospitals, and office-based hematologists/oncologists. … Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer. 2017;123:449–58. 5. …

Новые оценки издержек, связанных с неблагоприятными явлениями у больных раком.

Стоимость неблагоприятных явлений (ОЭ) является одним из важнейших компонентов экономических моделей здравоохранения для лечения раковых заболеваний; однако в настоящее время имеется мало всеобъемлющих оценок этих расходов. В предыдущих исследованиях основное внимание уделялось затратам, связанным с конкретными ПВ, типами рака или режимами лечения. В настоящем исследовании дается оценка дополнительных издержек, связанных с ЭВ, в различных областях 13 (Международная статистическая классификация болезней и связанных с ними проблем в области здравоохранения]ICD-10]) пациентам с диагнозом: 2016 и

Impact of Real-World Outpatient Cancer Rehabilitation Services on Health-Related Quality of Life of Cancer Survivors across 12 Diagnosis Types in the United States.

Compared to adults without cancer, cancer survivors report poorer health-related quality of life (HRQOL), which is associated with negative treatment outcomes and increased healthcare use. Cancer-specialized physical and occupational therapy (PT/OT) could optimize HRQOL; however, the impact among survivors with non-breast malignancies is unknown. This retrospective (2020-2022), observational, study of medical record data of 12 cancer types, examined pre/post-HRQOL among cancer survivors who completed PT/OT. PROMIS® HRQOL measures: Global Health (physical [GPH] and mental [GMH]), Physical Funct

Compassionate Communication and Advance Care Planning to improve End-of-life Care in Treatment of Haematological Disease 'ACT': Study Protocol for a Cluster-randomized trial.

IntroductionTo support the implementation of advance care planning and serious illness conversations in haematology, a previously developed conversation intervention titled 'Advance Consultations Concerning your Life and Treatment' (ACT) was found feasible. This study aims to investigate the effect of ACT on the quality of end-of-life care in patients with haematological malignancy and their informal caregivers.Methods and analysisThe study is a nationwide 2-arm cluster randomised trial randomising 40 physician-nurse clusters across seven haematological departments in Denmark to provide standa

Совпадение в полном тексте источника
… Perceived barriers to goals of care discussions with patients with advanced cancer and their families in the ambulatory setting: A multicenter survey of Oncologists. J Palliat Care 2018;33:125–42. 10.1177/0825859718762287 34. Granek L, Krzyzanowska MK, Tozer R, et al. … Oncologists' strategies and barriers to effective communication about the end of life. J Oncol Pract 2013;9:e129–35. 10.1200/JOP.2012.000800 35. Bernacki R, Hutchings M, Vick J, et al. …

The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age.

Fragility scales are intended to help in therapeutic decisions. Here, we asked if the fragility assessment in MM patients ≥ 75 years old qualified for treatment by the local physician correlates with the choice of treatment: a two- or three-drug regimens. Between 7/2018 and 12/2019, we prospectively enrolled 197 MM patients at the start of treatment from the 13 Polish Myeloma Group centers. The data to assess fragility were prospectively collected, but centrally assessed fragility was not disclosed to the local center. The activity of daily living (ADL) could be assessed in 192 (97.5%) and was

Совпадение в полном тексте источника
… Our data showed that even very old frail MM patients might benefit from the three-drug regimens administered by an experienced primary oncologist or hematologist. … Frailty—An overview for oncologists. Onkologia w Praktyce Klinicznej. 2010;6:5. 3. Łacko A. Specyfika leczenia chorych na nowotwory w podeszłym wieku. Medycyna Wieku Podeszłego. 2012;2:5. 4. …

Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic "Stromal" Cells from Giant Cell Tumors of Bone.

The neoplastic "stromal" cells in giant cell tumor of bone (GCTB) harbor a mutation in the H3F3A gene, which causes alterations in the epigenome. Current systemic targeted therapies, such as denosumab, do not affect the neoplastic cells, resulting in relapse upon treatment discontinuation. Therefore, this study examined whether targeting the epigenome could eliminate the neoplastic cells from GCTB. We established four novel cell lines of neoplastic "stromal" cells that expressed the H3F3A p.G34W mutation. These cell lines were used to perform an epigenetics compound screen (n = 128), which ide

Patient-reported symptom burden in routine oncology care: Examining racial and ethnic disparities.

BackgroundRacial and ethnic disparities are well-documented in cancer outcomes such as disease progression and survival, but less is known regarding potential disparities in symptom burden.AimsThe goal of this retrospective study was to examine differences in symptom burden by race and ethnicity in a large sample of cancer patients. We hypothesized that racial and ethnic minority patients would report greater symptom burden than non-Hispanic and White patients.Methods and resultsA total of 5798 cancer patients completed the Edmonton Symptom Assessment Scale-revised (ESAS-r-CSS) at least once a

Совпадение в полном тексте источника
… While research suggests that minority patients may have a better experience when treated by racially concordant providers, 43 only 2.3% of oncologists self‐identify as Black or African American and 5.8% as Hispanic, 44 suggesting that efforts are needed to increase representation of minorities in clinical … The effects of oncologist implicit racial bias in racially discordant oncology interactions. J Clin Oncol. 2016;34(24):2874‐2880. 43. Saha S, Komaromy M, Koepsell TD, Bindman AB. Patient‐physician racial concordance and the perceived quality and use of health care. …

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis.

IntroductionSeveral maintenance therapies are available for treatment of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). The objective of this review was to assess the efficacy and safety of lenalidomide monotherapy in these patients.MethodsMEDLINE, EMBASE, and the Cochrane Library databases were searched for publications up to April 7, 2021. Original studies that had information on lenalidomide monotherapy for DLBCL patients with R/R status were included. Meta-analyses of response rates, adverse events (AEs), overall survival (OS), and progression-free survival

Совпадение в полном тексте источника
… Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. AJR Am J Roentgenol (2010) 195:281–9. doi: 10.2214/AJR.09.4110 12. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES . … Lenalidomide in Pretreated Patients With Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. oncologist (2019) 24:1246–52. doi: 10.1634/theoncologist.2018-0603 23. Gribben JG, Fowler N, Morschhauser F. …

Perspectives on returning to work of multiple myeloma patients: A qualitative interview study.

ObjectiveMultiple myeloma (MM) is a rare and incurable disease. Because new treatments improved survival rates, return to work (RTW) became more relevant to MM patients of working age. Also, (health care) experts may be confronted with specific obstacles in guiding MM patients' RTW. Therefore, we aimed to qualitatively explore perspectives and experiences of MM patients and (health care) experts regarding RTW and participation at work.MethodsSemi-structured interviews were conducted with patients (N = 9) and (health care) experts (N = 15). Interviews were transcribed verbatim and analysed usin

Совпадение в полном тексте источника
… . | E A few years ago, there was talk of perhaps training specialised insurance physicians, … yes, that would be great but then you would also need to create some sort of consultation strategy with the oncologists . | E HCPs addressing RTW | We aren't saying that an oncologist should also be a labour …

Experiences with health care and health-related quality of life of patients with hematologic malignancies in Mexico.

BACKGROUND: In Mexico, patients with hematologic malignancies (HMs) are characterized by being at high risk and advanced stages at diagnosis and by having a low cure rate; yet information on their experiences with health care and health-related quality of life (HRQL) is scarce. We aimed to evaluate experiences with health care and HRQL of patients with HMs and the association between these patient-reported measures. METHODS: We conducted a cross-sectional survey in two public oncology hospitals in Mexico City. The study included outpatient cancer patients aged ≥18 years with a diagnosis of le

Совпадение в полном тексте источника
… Delivering high-quality cancer care is challenging in low- and middle-income countries due to shortages in specialized human resources, such as oncologists/hematologists, pathologists, radiologists, and transplantolologists of haematopoietic progenitor cells, among others. … Oncologist. 2019. 10.1634/theoncologist.2019-0348. 10.1634/theoncologist.2019-0348 PMC7160310 32297435 32. …